Αποτελέσματα Αναζήτησης
To find a site near you, please enter your location. View Trial Details. Condition. Moderna ID. mRNA-1403-P301. NCT ID. NCT06592794. Trial Title. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis.
11 Μαΐ 2023 · In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we assessed outcomes in ZUMA-1 after 5 years of follow-up.
28 Δεκ 2017 · In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma...
5 Νοε 2021 · Here, we report updated survival findings from the phase 2 portion of ZUMA-1 after 4 years of follow-up, including an evaluation of the association of OS with EFS. Methods: Eligible pts had refractory LBCL (diffuse LBCL, primary mediastinal B cell lymphoma, transformed follicular lymphoma).
5 Ιουν 2023 · Conclusions. At a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large B-cell lymphoma resulted in significantly longer overall...
27 Ιαν 2017 · This 2-year analysis of the multicentre ZUMA-1 trial shows that a substantial proportion of patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel can achieve durable responses with manageable long-term safety.
4 Ιουν 2020 · Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma Blood. 2020 Jun 4;135 (23):2106 ... Clinical Trial, Phase I Clinical Trial, Phase II Letter Multicenter Study Research Support, Non-U.S. Gov't ...
